In this sense, considering the role of HDAC6 in metastatic invasion and experimental data showing the potential of HDAC6 inhibition to overcome resistance to targeted therapy, HDAC6 may represent a relevant therapeutic target in metastatic CRC. Here, HDAC6 is linked to colorectal carcinoma.